Baxter seeks European advertising authorization for HyQ to take care of PI Baxter International Inc.

The aim of the analysis was to infuse HyQ at a three or four 4 week IG dosage within a site. The acute serious infection rate in the scholarly study was 0.025 per patient each year, which is below the mandatory efficacy threshold of just one 1.0. In the tolerability evaluation of HyQ, the most regularly reported adverse reactions had been infusion site reactions , headaches , exhaustion and pyrexia . Baxter will be presenting study results through the American University of Allergy, Asthma and Immunology annual conference in Boston in November.Can-Fite has recently received approximately $8 million in upfront and milestone obligations to time. We are disappointed from the fact that the stage 3 medical trial for the treatment of Dry Eye Syndrome didn’t meet up with the endpoints. We intend to learn the trial results and extract from the medical data received the lessons required for the effective advancement of Can-Fite's compounds in various indications. The actual fact that the protection profile of CF101 remains high and is certainly consistent is very encouraging and emphasizes an important advantage of CF101 compared to other drugs out there. Our recently released positive data from our RA stage IIb clinical study and the positive interim analysis of data regarding CF101 for the treatment of psoriasis, in which half of the sufferers treated with CF101 demonstrated clinically meaningful improvement, both demonstrate the potential of the A3AR agonist CF101 for autoimmune inflammatory indications.